Phibro Animal Health (NASDAQ:PAHC) CEO Jack Bendheim Sells 6,693 Shares of Stock

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 6,693 shares of Phibro Animal Health stock in a transaction that occurred on Friday, January 30th. The shares were sold at an average price of $40.09, for a total transaction of $268,322.37. Following the sale, the chief executive officer directly owned 31,980 shares of the company’s stock, valued at $1,282,078.20. This represents a 17.31% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Jack Bendheim also recently made the following trade(s):

• On Thursday, January 29th, Jack Bendheim sold 6,772 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.12, for a total value of $271,692.64.
• On Friday, January 23rd, Jack Bendheim sold 1,235 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.55, for a total value of $50,079.25.
• On Thursday, January 22nd, Jack Bendheim sold 13,158 shares of Phibro Animal Health stock. The shares were sold at an average price of $41.98, for a total value of $552,372.84.
• On Wednesday, January 21st, Jack Bendheim sold 14,687 shares of Phibro Animal Health stock. The stock was sold at an average price of $41.68, for a total value of $612,154.16.
• On Thursday, January 15th, Jack Bendheim sold 2,932 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.02, for a total value of $117,338.64.
• On Wednesday, January 14th, Jack Bendheim sold 3,651 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.53, for a total value of $147,975.03.
• On Tuesday, January 13th, Jack Bendheim sold 7,551 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.32, for a total value of $304,456.32.
• On Friday, January 9th, Jack Bendheim sold 213 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.16, for a total transaction of $8,554.08.
• On Wednesday, January 7th, Jack Bendheim sold 328 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.09, for a total transaction of $13,149.52.
• On Thursday, December 11th, Jack Bendheim sold 5,752 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.93, for a total transaction of $235,429.36.

Phibro Animal Health Price Performance

Shares of PAHC opened at $41.91 on Tuesday. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.35 and a current ratio of 3.09. The company has a 50 day moving average price of $39.85 and a 200-day moving average price of $37.96. Phibro Animal Health Corporation has a fifty-two week low of $16.16 and a fifty-two week high of $46.42. The stock has a market capitalization of $1.70 billion, a PE ratio of 25.25, a PEG ratio of 1.14 and a beta of 0.80.

Phibro Animal Health (NASDAQ:PAHC) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $0.73 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.15. The company had revenue of $363.89 million during the quarter, compared to the consensus estimate of $345.44 million. Phibro Animal Health had a net margin of 4.85% and a return on equity of 36.26%. Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. Equities analysts predict that Phibro Animal Health Corporation will post 1.95 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Phibro Animal Health by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,164 shares of the company’s stock valued at $260,000 after purchasing an additional 546 shares during the period. Millennium Management LLC increased its holdings in Phibro Animal Health by 74.3% during the 1st quarter. Millennium Management LLC now owns 362,030 shares of the company’s stock worth $7,733,000 after purchasing an additional 154,281 shares during the period. Jane Street Group LLC increased its stake in shares of Phibro Animal Health by 65.3% during the first quarter. Jane Street Group LLC now owns 33,917 shares of the company’s stock worth $724,000 after buying an additional 13,404 shares during the period. State of Alaska Department of Revenue raised its holdings in Phibro Animal Health by 7.6% in the second quarter. State of Alaska Department of Revenue now owns 12,129 shares of the company’s stock valued at $309,000 after acquiring an additional 859 shares in the last quarter. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its stake in Phibro Animal Health by 10.0% in the second quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 11,530 shares of the company’s stock worth $294,000 after acquiring an additional 1,044 shares during the last quarter. Institutional investors and hedge funds own 99.34% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Weiss Ratings reissued a “buy (b-)” rating on shares of Phibro Animal Health in a report on Monday, December 29th. Zacks Research raised shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 9th. Finally, JPMorgan Chase & Co. upped their price target on Phibro Animal Health from $45.00 to $50.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $31.40.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.